Superior discriminating value of ACTH-stimulated serum 21-deoxycortisol in identifying heterozygote carriers for 21-hydroxylase deficiency

Clinical Endocrinology

Volumn 73, Issue 6, 2010, Pages 700-706

  Costa Barbosa, Flávia A ^a   Tonetto Fernandes, Vânia F ^a   Carvalho, Valdemir M ^b   Nakamura, Odete H ^b   Moura, Vivian ^c   Bachega, Tânia A S S ^c   Vieira, José G H ^a,b   Kater, Claudio E ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b Fleury   (Brazil)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

21 DEOXYHYDROCORTISONE; CORTICOTROPIN; HYDROCORTISONE; HYDROXYPROGESTERONE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GENOTYPE; GESTAGEN BLOOD LEVEL; HETEROZYGOTE DETECTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYDROCORTISONE BLOOD LEVEL; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; STEROID 21 MONOOXYGENASE DEFICIENCY; TANDEM MASS SPECTROMETRY;

ADOLESCENT; ADRENAL HYPERPLASIA, CONGENITAL; ADRENOCORTICOTROPIC HORMONE; ADULT; CHILD; CHILD, PRESCHOOL; CHROMATOGRAPHY, LIQUID; CORTODOXONE; FEMALE; HETEROZYGOTE DETECTION; HUMANS; MALE; MIDDLE AGED; MUTATION; STEROID 21-HYDROXYLASE; TANDEM MASS SPECTROMETRY; YOUNG ADULT;

EID: 78649271788     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2010.03871.x     Document Type: Article

References (40)

1. White, P.C., &, Speiser, P.W., (2000) Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Endocrine Reviews, 21, 245 - 291.
2. Speiser, P.W., &, White, P.C., (2003) Congenital adrenal hyperplasia. New England Journal of Medicine, 349, 776 - 788.
3. Moran, C., Azziz, R., Weintrob, N., et al. (2006) Reproductive outcome of women with 21-hydroxylase-deficient nonclassic adrenal hyperplasia. Journal of Clinical Endocrinology and Metabolism, 91, 3451 - 3456.
4. New, M.I., (2006) Extensive clinical experience: nonclassical 21-hydroxylase deficiency. Journal of Clinical Endocrinology and Metabolism, 91, 4205 - 4214.
5. Forest, M.G., (2004) Recent advances in the diagnosis and management of congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Human Reproduction Update, 10, 469 - 485.
6. Azziz, R., Dewailly, D., &, Owerbach, D., (1994) Nonclassic adrenal hyperplasia: current concepts. Journal of Clinical Endocrinology and Metabolism, 78, 810 - 815.
7. Azziz, R., &, Dewailly, D., (1997) Diagnosis, screening, and treatment of nonclassic 21-hydroxylase deficiency. In:, R. Azziz, J.E. Nestler, D. Dewailly, eds. Androgen Excess Disorders in Women. Lippincott-Raven, Philadelphia, pp. 181 - 192.
8. Witchel, S.F., &, Lee, P.A., (1998) Identification of heterozygotic carriers of 21-hydroxylase deficiency: sensitivity of ACTH stimulation tests. American Journal of Medical Genetics, 76, 337 - 342.
9. Cassorla, F., Tenore, A., Parks, J.S., et al. (1980) Serum 21-deoxycortisol and 17-hydroxypregnenolone in parents of patients with congenital adrenal hyperplasia. Journal of Endocrinological Investigation, 3, 137 - 142.
10. Fiet, J., Gueux, B., Gourmelen, M., et al. (1988) Comparison of basal and adrenocorticotropin-stimulated plasma 21-deoxycortisol and 17- hydroxyprogesterone values as biological markers of late-onset adrenal hyperplasia. Journal of Clinical Endocrinology and Metabolism, 66, 659 - 667.
11. Tardy, V., Forest, M., De Rougemont, A., et al. (2005) Detection of heterozygotes for 21-hydroxylase deficiency: validation of 21-deoxycortisol after ACTH test by sequencing of the entire CYP21 gene. Hormone Research, 64 (Suppl. 1): 41 - 42.
12. Carvalho, V.M., Nakamura, O.H., &, Vieira, J.G., (2008) Simultaneous quantification of seven endogenous C-21 adrenal steroids by liquid chromatography tandem mass spectrometry in human serum. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences, 872, 154 - 161.
13. Tholen, D.W., Linnet, K., Kondratovich, M., et al. (2004) Protocols for determination of limits of detection and limits of quantification; Approved guideline (NCCLS document EP17-A, ISBN 1-56238-551-8). Clinical and Laboratory Standards Institute (CSLI), 24, 1 - 39.
14. Bachega, T.A., Brenlha, E.M., Billerbeck, A.E., et al. (2002) Variable ACTH-stimulated 17-hydroxyprogesterone values in 21-hydroxylase deficiency carriers are not correlated to different CYP21 gene mutations. Journal of Clinical Endocrinology and Metabolism, 87, 786 - 790.
15. Billerbeck, A.E., Mendonca, B.B., Pinto, E.M., et al. (2002) Three novel mutations in CYP21 gene in Brazilian patients with the classic form of 21-hydroxylase deficiency due to a founder effect. Journal of Clinical Endocrinology and Metabolism, 87, 4314 - 4317.
16. Mota, E.R., Bachega, T.A., Nishi, M.Y., et al. (2008) Comparison between Southern Blot and Multiplex Ligation Probe amplification techniques for detection of large rearrangements involving CYP21 genes in patients with 21-hydroxylase deficiency. Program of the the Annual Meeting of the Endocrine Society, San Francisco, SF, 2008; 500 pp.
17. New, M.I., Lorezen, F., Lerner, A.J., et al. (1983) Genotyping steroid 21-hydroxylase deficiency: hormonal reference data. Journal of Clinical Endocrinology and Metabolism, 92, 4028 - 4034.
18. Speiser, P.W., Dupont, J., Zhu, D., et al. (1992) Disease expression and molecular genotype in congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Journal of Clinical Investigation, 90, 584 - 595.
19. Tonetto-Fernandes, V., Lemos-Marini, S.H., Kuperman, H., et al. (2006) Serum 21-deoxycortisol, 17-hydroxyprogesterone, and 11-deoxycortisol in classic congenital adrenal hyperplasia: clinical and hormonal correlations and identification of patients with 11 beta-hydroxylase deficiency among a large group with alleged 21-hydroxylase deficiency. Journal of Clinical Endocrinology and Metabolism, 91, 2179 - 2184.
20. Janzen, N., Peter, M., Sander, S., et al. (2007) Newborn screening for congenital hyperplasia: additional steroid profile using liquid chromatography-tandem mass spectrometry. Journal of Clinical Endocrinology and Metabolism, 92, 2581 - 2589.
21. Krensky, A.M., Bongiovanni, A.M., Marino, J., et al. (1977) Identification of heterozygote carriers of congenital adrenal hyperplasia by radioimmunoassay of serum 17-OH progesterone. The Journal of Pediatrics, 90, 930 - 933.
22. Gourmelen, M., Gueux, B., Pham-Huu-Trung, M.T., et al. (1987) Detection of heterozygote carrier for 21-hydroxylase deficiency by plasma 21-deoxycortisol measurements. Acta Endocrinologica, 116, 507 - 512.
23. Fiet, J., Villette, J.M., Galons, H., et al. (1994) The application of a new highly-sensitive radioimmunoassay for plasma 21-deoxycortisol to the detection of steroid 21-hydroxylase deficiency. Annals of Clinical Biochemistry, 31, 56 - 64.
24. Glintborg, D., Hermann, A.P., Brusgaard, K., et al. (2005) Significantly higher adrenocorticotropin-stimulated cortisol and 17-hydroxyprogesterone levels in 337 consecutive, premenopausal, caucasian, hirsute patients compared with healthy controls. Journal of Clinical Endocrinology and Metabolism, 90, 1347 - 1353.
25. Gutai, J.P., Kowarski, A.A., &, Migeon, C.J., (1977) The detection of the heterozygous carrier for congenital virilizing adrenal hyperplasia. The Journal of Pediatrics, 90, 924 - 929.
26. Knorr, D., Bidlingmaier, F., Höller, W., et al. (1983) Diagnosis of homozygosity and heterozygosity in congenital adrenal hyperplasia (CAH) and control of treatment. Journal of Steroid Biochemistry, 19, 645 - 653.
27. Pardini, D.P., Kater, C.E., Vieira, J.G., et al. (1983) Impaired mineralocorticoid hormone responses to adrenocorticotropin stimulation: additional characterization of heterozygosity for the 21-hydroxylase deficiency type of congenital adrenal hyperplasia. Journal of Clinical Endocrinology and Metabolism, 57, 1061 - 1066.
28. Peter, M., Sippell, W.G., Lorenzen, F., et al. (1990) Improved test to identify heterozygotes for congenital adrenal hyperplasia without index case examination. Lancet, 335, 1296 - 1299.
29. Fiet, J., Boudi, A., Giton, F., et al. (2000) Plasma 21-deoxycortisol: comparison of a time-resolved fluoroimmunoassay using a biotinylated tracer with a radioimmunoassay using (125) iodine. Journal of Steroid Biochemistry, 72, 55 - 60.
30. Fernandes, V.T., Ribeiro-Neto, L.M., Lima, S.B., et al. (2003) Reversed-phase high-performance liquid chromatography separation of adrenal steroids prior to radioimmunoassay: application in congenital adrenal hyperplasia. Journal of Chromatographic Science, 41, 251 - 254.
31. Kao, P.C., Machacek, D.A., Magera, M.J., et al. (2001) Diagnosis of adrenal cortical dysfunction by liquid chromatography-tandem mass spectrometry. Annals of Clinical and Laboratory Science, 31, 199 - 204.
32. Minutti, C.Z., Lacey, J.M., Magera, M.J., et al. (2004) Steroid profiling by tandem mass spectrometry improves the predictive value of newborn screening for congenital adrenal hyperplasia. Journal of Clinical Endocrinology and Metabolism, 89, 3687 - 3693.
33. Cristoni, S., Cuccato, D., Sciannamblo, M., et al. (2004) Analysis of 21-deoxycortisol, a marker of congenital adrenal hyperplasia, in blood by atmospheric pressure chemical ionization and electrospray ionization using multiple reaction monitoring. Rapid Communications in Mass Spectrometry, 18, 77 - 82.
34. Blanché, H., Vexiau, P., Clauin, S., et al. (1997) Exhaustive screening of 21-hydroxylase gene in a population of hyperandrogenic women. Human Genetics, 101, 56 - 60.
35. Bidet, M., Bellanné-Chantelot, C., Galand-Portier, M.B., et al. (2009) Clinical and molecular characterization of a cohort of 161 unrelated women with nonclassical congenital adrenal hyperplasia due to 21-hydroxylase deficiency and 330 family members. Journal of Clinical Endocrinology and Metabolism, 94, 1570 - 1578.
36. Escobar-Morreale, H.F., San Millán, J.L., Smith, R.R., et al. (1999) The presence of the 21-hydroxylase deficiency carrier status in hirsute women: phenotype-genotype correlations. Fertility and Sterility, 72, 629 - 638.
37. Admoni, O., Israel, S., Lavi, I., et al. (2006) Hyperandrogenism in carriers of CYP21 mutations: the role of genotype. Clinical Endocrinology, 64, 645 - 651.
38. Witchel, S.F., &, Aston, C.E., (2000) The role of heterozygosity for CYP21 in the polycystic ovary syndrome. Journal of Pediatric Endocrinology and Metabolism, 13 (Suppl. 5): 1315 - 1317.
39. Deneux, C., Tardy, V., Dib, A., et al. (2001) Phenotype-genotype correlation in 56 women with nonclassical congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Journal of Clinical Endocrinology and Metabolism, 86, 207 - 213.
40. Bachega, T.A., Billerbeck, A.E., Marcondes, J.A., et al. (2000) Influence of different genotypes on 17-hydroxyprogesterone levels in patients with non-classical congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Clinical Endocrinology, 52, 601 - 607.